In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...
Data provide further insight into how the timing of PCI may affect outcomes in STEMI patients at risk for future cardiovascular events ORLANDO, Fla., Nov. 16, 2011 /PRNewswire/ -- An analysis of the ...
Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...
Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...
Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening ProcedureStudy did ...
When choosing a P2Y12 inhibitor to use in combination with aspirin in patients with diabetes undergoing percutaneous coronary intervention (PCI) for multivessel disease, prasugrel may be preferable to ...
NEW ORLEANS, LA—Ticagrelor did not prove to be noninferior to prasugrel as part of dual antiplatelet therapy (DAPT) following PCI in patients with diabetes and multivessel coronary disease in the ...
A newly approved drug thins the blood faster, more consistently, and more powerfully than the standard drug, which can fail to prevent deadly blood clots in patients after they undergo a common ...
Please provide your email address to receive an email when new articles are posted on . In the ISAR-REACT 5 randomized trial, Maurizio Menichelli, MD, head of cardiology at Fabrizio Spaziani Hospital ...
--Effient(TM) Reduces Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndromes Managed with Common Artery-Opening Procedure PARSIPPANY, N.J. and INDIANAPOLIS, July 10, 2009 ...
INDIANAPOLIS and TOKYO, Aug. 15, 2011 /PRNewswire/ -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results